{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Genetics&page=63",
    "query": {
      "condition": "Cancer Genetics",
      "page": 63
    },
    "page_size": 10
  },
  "pagination": {
    "page": 63,
    "page_size": 10,
    "total_count": 1625,
    "total_pages": 163,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Genetics&page=64&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Genetics&page=62&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T13:41:58.230Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02614794",
      "title": "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 612,
      "start_date": "2016-01-28",
      "completion_date": "2022-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614794"
    },
    {
      "nct_id": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "PF-07934040",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluorouracil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Oxaliplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Leucovorin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bevacizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sasanlimab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2024-06-27",
      "completion_date": "2026-10-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 26,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06447662"
    },
    {
      "nct_id": "NCT05059327",
      "title": "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex"
      ],
      "interventions": [
        {
          "name": "Basimglurant with crossover to Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo with crossover to Basimglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noema Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "5 Years to 30 Years"
      },
      "enrollment_count": 61,
      "start_date": "2022-03-03",
      "completion_date": "2025-04-28",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Roseville",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059327"
    },
    {
      "nct_id": "NCT03833661",
      "title": "M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Biliary Tract Cancer",
        "Cholangiocarcinoma",
        "Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "M7824",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2019-03-26",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-25",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03833661"
    },
    {
      "nct_id": "NCT06725173",
      "title": "Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinoblastoma Bilateral",
        "Retinoblastoma Unilateral",
        "Retinoblastoma, Extraocular",
        "Retinoblastoma, Recurrent",
        "Retinoblastoma"
      ],
      "interventions": [
        {
          "name": "Targeted Long-read sequencing",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2026-03-16",
      "completion_date": "2031-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06725173"
    },
    {
      "nct_id": "NCT04367246",
      "title": "Li-Fraumeni Syndrome/TP53 Biobank",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Li-Fraumeni Syndrome",
        "Li-Fraumeni-Like Syndrome"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 300,
      "start_date": "2019-09-24",
      "completion_date": "2029-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Phildelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Phildelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04367246"
    },
    {
      "nct_id": "NCT01582841",
      "title": "Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colon Cancer",
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "MSI screening test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 247,
      "start_date": "2012-02",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-31",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582841"
    },
    {
      "nct_id": "NCT03108066",
      "title": "MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL Gene Mutation",
        "VHL",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "Von Hippel",
        "Von Hippel-Lindau Disease",
        "Von Hippel's Disease",
        "Von Hippel-Lindau Syndrome, Modifiers of",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "MK-3795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-04-24",
      "completion_date": "2023-09-27",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108066"
    },
    {
      "nct_id": "NCT00341341",
      "title": "Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 757,
      "start_date": "2004-12-07",
      "completion_date": "2010-07-16",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00341341"
    },
    {
      "nct_id": "NCT02415153",
      "title": "Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis Type 1",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Visual Pathway Glioma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Refractory Primary Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "3 Years to 20 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-07-14",
      "completion_date": "2020-05-27",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-07T13:41:58.230Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02415153"
    }
  ]
}